PYMNTS.com January 21, 2025

Nobel laureate and Google DeepMind CEO Demis Hassabis said Tuesday (Jan. 21) that he expects to see pharmaceutical drugs designed by artificial intelligence (AI) to be in clinical trials by the end of the year.

During a fireside chat at the World Economic Forum in Davos, Switzerland, Hassabis said these drugs are being developed at Isomorphic Labs, a for-profit venture created by Google parent firm Alphabet in 2021 that was tasked to reinvent the entire drug discovery process based on first principles and led by AI.

“That’s the plan,” Hassabis said.

While large language models have taken the spotlight, Hassabis said that the field of AI as it applies to science is “a lot richer than just the language models...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Clinical Trials, Conferences / Podcast, Pharma, Pharma / Biotech, Technology, Trends
Creating Value: How Data, AI, And Apps Transform Business
Study sheds new light on brain evolution
Merck Is Embracing AI, But ‘We Always Have a Human in the Loop,’ Exec Says
AI-Powered Monitoring Meets 24/7 Virtual Care: BioIntelliSense and Hicuity Health Collaboration
iPhone Users Relentlessly Mock ‘Dumb’ Apple Intelligence

Share This Article